Pérez-Martínez, LauraRomero, LourdesMuñoz-Galván, SandraVerdugo-Sivianes, Eva MRubio-Mediavilla, SusanaOteo, José ACarnero, AmancioBlanco, José-Ramón2023-02-082023-02-082020-04-30http://hdl.handle.net/10668/15471As age increases, the risk of developing fragility also increases. Improving the knowledge of frailty could contribute to maintaining the functional ability of elderly people. Interleukin (IL)-10 homozygous knockout mice (IL-10tm/tm [IL10KO]) constitute an excellent tool for the study of frailty. Because patients with frailty demonstrate an overexpression of CCR5, rapamycin (RAPA) and/or maraviroc (MVC), two molecules able to decrease CCR5 expression, were evaluated. Muscle myostatin was reduced in all the therapeutic groups but the MVC group (p MVC and RAPA show a protective role in some factors involved in frailty. More studies are needed to prove their clinical applications. Eighty male homozygous IL10KOs were randomly assigned to one of 4 groups (n= 20): i) IL10KO group (IL10KO); ii) IL10KO receiving MVC in drinking water (MVC group), iii) IL10KO receiving RAPA in drinking water (RAPA group), and finally, iv) MVC-RAPA group that received MVC and RAPA in drinking water. Blood and muscle samples were analysed. Survival analysis, frailty index calculation, and functional assessment were also performed.enAttribution 4.0 Internationalhttp://creativecommons.org/licenses/by/4.0/CCR5 antagonistfrailtymyostatinrapamycinAgingAnimalsCytokinesDisease Models, AnimalFrailtyInterleukin-10MaleMaravirocMiceMice, KnockoutMuscle, SkeletalRandom AllocationReceptors, ChemokineSirolimusSurvival Rateresearch article32353830open access10.18632/aging.1031671945-4589PMC7244075https://doi.org/10.18632/aging.103167https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7244075/pdf